Leads Biolabs Secures US FDA Orphan Drug Status for LBL-024 Antibody Targeting Neuroendocrine Cancer
Nanjing-based Leads Biolabs Co., Ltd., a clinical-stage biotechnology firm established by a team of experienced antibody drug developers trained in the United States, has announced a major advancement in the development of its proprietary bispecific antibody, LBL-024. The United States […]